D
Douglas H. Thamm
Researcher at Colorado State University
Publications - 205
Citations - 7604
Douglas H. Thamm is an academic researcher from Colorado State University. The author has contributed to research in topics: Cancer & Osteosarcoma. The author has an hindex of 42, co-authored 192 publications receiving 6559 citations. Previous affiliations of Douglas H. Thamm include University of Wisconsin-Madison & Arizona's Public Universities.
Papers
More filters
Journal ArticleDOI
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee Honigberg,Ashley M. Smith,Mint Sirisawad,Erik Verner,David Loury,Betty Y. Chang,Shyr Li,Zhengying Pan,Douglas H. Thamm,Richard A. Miller,Joseph J. Buggy +10 more
TL;DR: Findings support Btk inhibition as a therapeutic approach for the treatment of human diseases associated with activation of the BCR pathway.
Journal ArticleDOI
Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document
TL;DR: The human response evaluation criteria in solid tumours is used as a framework to establish standard procedures for response assessment in canine solid tumour assessment that is meant to be easy to use, repeatable and applicable across a variety of clinical trial structures in veterinary oncology.
Journal ArticleDOI
Polymer-modified gadolinium metal-organic framework nanoparticles used as multifunctional nanomedicines for the targeted imaging and treatment of cancer.
TL;DR: These versatile, nanoscale scaffolds were shown to be biocompatible and have cancer cell targeting, bimodal imaging, and disease treatment capabilities.
Journal ArticleDOI
An Asymmetric Synthesis of 1,2,4-Trioxane Anticancer Agents via Desymmetrization of Peroxyquinols through a Brønsted Acid Catalysis Cascade
TL;DR: The desymmetrization of p-peroxyquinols using a Brønsted acid-catalyzed acetalization/oxa-Michael cascade was achieved in high yields and selectivities for a variety of aliphatic and aryl aldehydes.
Journal ArticleDOI
Prednisone and Vinblastine Chemotherapy for Canine Mast Cell Tumor—41 Cases (1992–1997)
TL;DR: Forty-one dogs with mast cell tumors were treated with oral prednisone and injectable vinblastine, both in the adjuvant setting and in dogs with gross disease, with apparent improvement over historical survival data employing surgery alone.